Gil Blum
Stock Analyst at Needham
(3.94)
# 574
Out of 5,154 analysts
416
Total ratings
40.71%
Success rate
13.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Reiterates: Buy | $10 | $4.57 | +118.82% | 32 | Mar 3, 2026 | |
| IMCR Immunocore Holdings | Maintains: Buy | $71 → $75 | $32.97 | +127.48% | 15 | Feb 26, 2026 | |
| ACLX Arcellx | Downgrades: Hold | n/a | $114.33 | - | 26 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $80 → $82 | $56.50 | +45.13% | 28 | Feb 13, 2026 | |
| MREO Mereo BioPharma Group | Maintains: Buy | $5 → $3 | $0.39 | +661.23% | 21 | Jan 13, 2026 | |
| AUTL Autolus Therapeutics | Maintains: Buy | $11 → $10 | $1.51 | +562.25% | 34 | Jan 12, 2026 | |
| GERN Geron | Reiterates: Buy | $5 | $1.53 | +226.80% | 23 | May 2, 2024 | |
| RXRX Recursion Pharmaceuticals | Reiterates: Buy | $8 | $3.46 | +131.21% | 26 | Feb 26, 2026 | |
| SLDB Solid Biosciences | Reiterates: Buy | $16 | $6.75 | +137.04% | 3 | Feb 9, 2026 | |
| NRIX Nurix Therapeutics | Reiterates: Buy | $26 | $15.10 | +72.19% | 29 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $6.85 | +513.14% | 16 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $14.34 | - | 8 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $2.38 | +194.12% | 7 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $6 | $1.12 | +435.71% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.33 | - | 9 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $115.00 | -39.13% | 21 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $5.74 | +213.59% | 7 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.50 | +300.00% | 18 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | n/a | $16.71 | - | 38 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | n/a | $4.41 | - | 22 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $5.99 | - | 16 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $12.07 | +297.68% | 9 | Aug 2, 2024 |
Taysha Gene Therapies
Mar 3, 2026
Reiterates: Buy
Price Target: $10
Current: $4.57
Upside: +118.82%
Immunocore Holdings
Feb 26, 2026
Maintains: Buy
Price Target: $71 → $75
Current: $32.97
Upside: +127.48%
Arcellx
Feb 23, 2026
Downgrades: Hold
Price Target: n/a
Current: $114.33
Upside: -
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Buy
Price Target: $80 → $82
Current: $56.50
Upside: +45.13%
Mereo BioPharma Group
Jan 13, 2026
Maintains: Buy
Price Target: $5 → $3
Current: $0.39
Upside: +661.23%
Autolus Therapeutics
Jan 12, 2026
Maintains: Buy
Price Target: $11 → $10
Current: $1.51
Upside: +562.25%
Geron
May 2, 2024
Reiterates: Buy
Price Target: $5
Current: $1.53
Upside: +226.80%
Recursion Pharmaceuticals
Feb 26, 2026
Reiterates: Buy
Price Target: $8
Current: $3.46
Upside: +131.21%
Solid Biosciences
Feb 9, 2026
Reiterates: Buy
Price Target: $16
Current: $6.75
Upside: +137.04%
Nurix Therapeutics
Jan 29, 2026
Reiterates: Buy
Price Target: $26
Current: $15.10
Upside: +72.19%
Jan 9, 2026
Maintains: Buy
Price Target: $40 → $42
Current: $6.85
Upside: +513.14%
Dec 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $14.34
Upside: -
Dec 12, 2025
Reiterates: Buy
Price Target: $7
Current: $2.38
Upside: +194.12%
Nov 4, 2025
Maintains: Buy
Price Target: $9 → $6
Current: $1.12
Upside: +435.71%
Oct 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.33
Upside: -
Oct 20, 2025
Reiterates: Buy
Price Target: $70
Current: $115.00
Upside: -39.13%
Oct 17, 2025
Reiterates: Buy
Price Target: $18
Current: $5.74
Upside: +213.59%
Aug 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.50
Upside: +300.00%
Jul 29, 2025
Reiterates: Underperform
Price Target: n/a
Current: $16.71
Upside: -
Jul 24, 2025
Maintains: Hold
Price Target: n/a
Current: $4.41
Upside: -
Mar 27, 2025
Reiterates: Hold
Price Target: n/a
Current: $5.99
Upside: -
Aug 2, 2024
Reiterates: Buy
Price Target: $48
Current: $12.07
Upside: +297.68%